表紙
市場調査レポート

Evacetrapib(急性冠症候群)- 予測と市場分析

Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 312387
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Evacetrapib(急性冠症候群)- 予測と市場分析 Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
出版日: 2014年07月31日 ページ情報: 英文 86 Pages
概要

急性冠症候群(ACS)の現在の市場は、主として抗血栓剤、抗高血圧剤、スタチンで構成され、標準治療として十分に確立されているため、その多くはジェネリック医薬品です。ACS市場は、圧倒的多数の生活習慣病(肥満など)を伴う高齢化人口、代謝異常(糖尿病など)の有病率の増加によって、今後も成長が予測されています。

当レポートでは、ACSの治療薬であるEvacetrapibについて調査分析し、疾患の概要と治療ガイドライン、競合情勢、製品情報、売上予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
    • QOL
  • 症状

第4章 疾患の管理

  • 治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 アンメットニーズと機会

  • 概要
  • アテローム性動脈硬化プラークの直接的な治療法
  • 繊維性心筋症と関連する併存疾患の治療法
  • スタチン不耐性・難治性・不適合患者に対するLDLコレステロール低下薬
  • 新型経口抗凝固剤(NOAC)に対する解毒剤
  • 出血リスクを大幅に低下させた抗凝血剤

第7章 パイプライン評価

  • 概要
  • 臨床試験:相別、進捗状況別
  • 臨床開発中の有望な薬剤

第8章 Evacetrapib

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床的位置付け
  • 潜在的な商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

目次

GlobalData has released its new PharmaPoint Drug Evaluation report, "Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

In addition to Merck's anacetrapib, Eli Lilly will be vying for space in the cholesterol market with its own Phase III CETP inhibitor, evacetrapib. Like the researchers at Merck, the CETP inhibitor team at Eli Lilly believes they have learned from the torcetrapib and dalcetrapib clinical trial failures. As with any aspirational LDL-C treatment, Eli Lilly had to demonstrate the LDL-C lowering capacity of evacetrapib.

Scope

  • Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Aricept for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for ACS
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Aricept performance
  • Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Antidotes for New Oral Anticoagulants (NOACs)
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Blood-Thinning Agents with Significantly Reduced Bleeding Risks
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trials by Phase and Trial Status
  • 7.3. Promising Drugs in Clinical Development

8. Evacetrapib

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement

8.8. SWOT Analysis

  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population
    • 9.4.2. Diagnosed Acute Coronary Syndrome Patients
    • 9.4.3. Percent Drug-Treated Patients
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Generic Erosion
    • 9.4.6. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Reviewer
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Antiplatelet Agents that Inhibit Platelet Activation
  • Table 2: Anticoagulants that Inhibit the Coagulatory Cascade
  • Table 3: Symptoms of Acute Coronary Syndrome
  • Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
  • Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014
  • Table 6: Leading Treatments for Acute Coronary Syndrome, 2014
  • Table 7: Unmet Need and Opportunity in Acute Coronary Syndrome
  • Table 8: Acute Coronary Syndrome - Clinical Trials by Phase and Status, 2014
  • Table 9: Acute Coronary Syndrome - Late-Stage Pipeline, 2014
  • Table 10: Comparison of Therapeutic Classes in Development for ACS, 2014
  • Table 11: Product Profile - Evacetrapib
  • Table 12: Evacetrapib SWOT Analysis, 2013
  • Table 13: Global Sales Forecasts ($m) for Evacetrapib, 2013-2023
  • Table 14: Price Sources and Calculations, by Country
  • Table 15: Physicians Surveyed, By Country

List of Figures

  • Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast
  • Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome
  • Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis
  • Figure 4: Electrocardiography in the Diagnosis of ACS
  • Figure 5: Acute Coronary Syndrome Therapeutics - Clinical Trials by Phase in the 7MM, 2014
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents for ACS, 2013-2023
Back to Top